For a long time you, others and I have stated how low the MC has become. Now the EV is almost Zero, depending on how much cash, 5-10m?, is at hand.
The market, not just here, really went from 100% potential and who cares about income to 100% income and who cares about potential.
It should have been a combo of the above with increasing progress a slowly increase in sp.
2 years ago the tech valuations overshot to the upside, now to the downside.
I personally compare CHM to IMU my way, SOI, number and status of the platforms. About 1/ 15 of SOI, about 1/20 of EV, but about 1/4 to even 1/3 of potential.
That way I think CHM will be an even better investment from here especially when current sp levels of 3c to 4c ranges aren't far apart.
It all depends on the data announced on Tuesday or maybe tomorrow and, that's even more important, how the local market values them. The wording is of vital importance, any non bio- expert need to be able to understand it.
In the end we actually only need 2 parties to put the correct value onto it, management and big pharma. What ever they agree to should reflect a fair market value. Let's hope Hopper will be " greedy " for us and not just for his mates as recently demonstrated at IMU. Should the sp move significantly north then my " board seat " attempt would be financially impossible at this stage, an opportunity I would be glad to see slipping away.
If the data come out as hoped for but the market isn't positively reacting then we either have to promote CHM like hell to open the market's eyes or continue to quietly accumulate until someone big gets the message.
GLTA
Expand
(20min delay)